Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03020238
Other study ID # PUMCH-OBGYN-2013
Secondary ID
Status Completed
Phase N/A
First received January 11, 2017
Last updated January 12, 2017
Start date January 2013
Est. completion date January 2017

Study information

Verified date January 2017
Source Peking Union Medical College Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Radical hysterectomy is an important therapy for early cervical cancer. Disfunction of urinary dynamics is the most common postoperative adverse effects, which had negative impact on patients' quality of life. Nerve sparing radical hysterectomy (NSRH) could reserve inferior hypogastric plexus (IHP) innervating bladder, hence improving postoperative urinary dynamics. Furthermore impact of different energy instruments on urinary dynamic isn't clear.

Objectives: This study is to compare urinary dynamics before and after NSRH, and to analyze the difference between BiClamp forcep (BiClamp® forcep, ERBE Elektromedizin, GmbH, Tuebingen, Germany) and water jet (ERBEJET®2) about the effects of dissecting IHP.

Study population: Cervical cancer of FIGO IB stage, among which 120 cases are enrolled to randomly allocated to BiClamp group or water jet group.

Intervention: Patients accept NSRH which all will be accomplished by Professor Ming Wu.

Methods: All surgical patients are accessed via urinary dynamics before and four months after NSRH. On the 14th day after surgeries, urinary catheter will be removed and residual urine volume (RUV) will be measured. For patients of RUV > 100 ml, urinary catheter will be replaced.

Primary study endpoint: the successful rate of removing urinary catheter on the 14th day after NSRH.

Secondary study endpoint: urinary dynamics four months after NSRH.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date January 2017
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- FIGO stage IB

- ASA score 0-2

Exclusion Criteria:

- Radiotherapy or chemotherapy before surgeries

- ASA score > 2

- With abnormal urinary dynamics before surgeries

Study Design


Intervention

Procedure:
BiClamp group
electric energy
water jet group
water jet energy

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Peking Union Medical College Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary successful rate of removing urinary catheter successful rate (%) of removing urinary catheter assessed by residual urine volume less than 100 ml 14th day after nerve-sparing radical hysterectomy
Secondary urinary dynamics parameters determined by urodynamics apparatus: bladder capacity and sensation bladder capacity and sensation in ml four months after nerve-sparing radical hysterectomy
Secondary urinary dynamics parameters determined by urodynamics apparatus: residual urine volume residual urine volume in ml four months after nerve-sparing radical hysterectomy
Secondary urinary dynamics parameters determined by urodynamics apparatus: urine flow rate urine flow rate in ml/s four months after nerve-sparing radical hysterectomy
Secondary urinary dynamics parameters determined by urodynamics apparatus: bladder pressure bladder pressure in cmH2O four months after nerve-sparing radical hysterectomy
Secondary urinary dynamics parameters determined by urodynamics apparatus: detrusor pressure detrusor pressure in cmH2O four months after nerve-sparing radical hysterectomy
Secondary urinary dynamics parameters determined by urodynamics apparatus: bladder compliance bladder compliance in ml/cmH2O four months after nerve-sparing radical hysterectomy
Secondary survival outcomes: ovarall survival overall survival in months two years after nerve-sparing radical hysterectomy
Secondary survival outcomes: progression-free survival progression-free survival in months two years after nerve-sparing radical hysterectomy
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A